A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Pevonedistat in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Pevonedistat in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2018

At a glance

  • Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 25 May 2018 Planned End Date changed from 3 May 2018 to 30 Sep 2018.
    • 25 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 25 May 2018 Planned End Date changed from 3 May 2019 to 3 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top